Fibroblast growth factor 23 is related to profiles indicating volume overload, poor therapy optimization and prognosis in patients with new-onset and worsening heart failure.
Ter Maaten JM, Voors AA, Damman K, van der Meer P, Anker SD, Cleland JG, Dickstein K, Filippatos G, van der Harst P, Hillege HL, Lang CC, Metra M, Navis G, Ng L, Ouwerkerk W, Ponikowski P, Samani NJ, van Veldhuisen DJ, Zannad F, Zwinderman AH, de Borst MH.
Ter Maaten JM, et al. Among authors: de borst mh.
Int J Cardiol. 2018 Feb 15;253:84-90. doi: 10.1016/j.ijcard.2017.10.010.
Int J Cardiol. 2018.
PMID: 29306478
Free article.